Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 5/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341222 | 0.81 | MAOA (0.43) | TTRCES1L3MBTL1CA12CA1 | |
| SCHEMBL17837184 | 0.80 | NR1H2 (0.53) | TTRDRD2NR1H2NR1H3MAPT | |
| SCHEMBL16430890 | 0.80 | NR1H2 (0.53) | TTRDRD2NR1H2NR1H3MAPT | |
| SCHEMBL16430440 | 0.79 | NR1H2 (0.41) | DRD2NR1H2NR1H3L3MBTL1KDM4E | |
| SCHEMBL12142309 | 0.79 | TDP1 (0.37) | TTRCES1RAB9ANPC1MAPT | |
| SCHEMBL17059929 | 0.77 | CASP3 (0.36) | TTRCES1CASP3DRD2HTR6 | |
| SCHEMBL17837188 | 0.75 | DRD2 (0.60) | DRD2RAB9AMAPTKDM4ELMNA | |
| SCHEMBL16127516 | 0.75 | TTR (0.75) | TTRCES1CASP3DRD2HTR6 | |
| SCHEMBL16430870 | 0.72 | DRD2 (0.62) | DRD2MAPTALDH1A1HPGD | |
| SCHEMBL12059596 | 0.71 | TTR (0.69) | TTRCES1CASP3DRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-7279573-B2 | Amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279573-B2 | Amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | TTR 4416/4885CES1 460/4885CASP3 3283/4885 |
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | GHRHR, NPPA, SSTR5 | TTR 1697/4885CES1 758/4885CASP3 2026/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | TTR 4874/4885CES1 689/4885CASP3 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.